Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their experience on day 9 after a hair transplant, mentioning the use of vitamin E oil and conditioner to remove scabs. They received positive feedback on their progress and were advised to be patient for noticeable results in a few months.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

A 23 year old's 9 month progress with hair regrowth using finasteride, minoxidil and keto shampoo, and others sharing their experiences and results with similar treatments.

The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The user has been using finasteride, minoxidil, microneedling, PRP, and ProCell therapy for hair loss but sees no progress after nine months. They are considering switching to dutasteride and possibly a hair transplant, with suggestions to add oral minoxidil.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

A user shared a 9-month hair loss treatment update using scalp micropigmentation (SMP), finasteride, minoxidil, derma pen, ketoconazole shampoo, and low-level laser therapy (LLLT), with plans for a hair transplant. Another person suggested increasing the dosage of finasteride and minoxidil and using a derma roller weekly.

People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

A 35-year-old has seen no hair regrowth after 9 months using treatments including finasteride, pyrilutamide, microneedling, ketoconazole shampoo, and topical dutasteride, but experienced side effects with RU58841. Commenters suggest starting minoxidil for better results and question why it wasn't included from the beginning.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.

A user shared a 9-month update on using 0.25mg finasteride daily for hair maintenance, reporting no significant side effects and considering whether to add other treatments like a dermastamp or ketoconazole. The user has not used minoxidil, believes it's unnecessary unless hair loss is severe, and occasionally takes biotin supplements.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

A user shared their 9-month hair loss treatment progress using oral finasteride, oral minoxidil, a topical solution with minoxidil and finasteride, microneedling, and ketoconazole shampoo. They are happy with the results and considering whether a hair transplant will be necessary.

A 24-year-old has been using finasteride, minoxidil, and ketoconazole shampoo for 9 months to address hair loss, reporting slow but noticeable progress with some regrowth. They also occasionally used a dermastamp and shared photos to show their progress.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

A user shared their 9-month progress using 1mg daily finasteride, noting initial side effects like low libido and ED that resolved over time, and advised staying on the treatment for at least a year before considering a hair transplant. Other users suggested adding minoxidil for better results and recommended using ketoconazole shampoo for dandruff.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The conversation is about the potential benefits of Rapamycin for hair pigmentation and regeneration, based on effects observed in mice. The original poster is seeking personal experiences from others using Rapamycin for longevity.